2,404 Shares in Amgen Inc. $AMGN Purchased by Churchill Financial Advisors LLC

Churchill Financial Advisors LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,404 shares of the medical research company’s stock, valued at approximately $787,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Dogwood Wealth Management LLC lifted its stake in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares in the last quarter. Anfield Capital Management LLC lifted its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC lifted its stake in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC purchased a new stake in Amgen during the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on AMGN. Daiwa Securities Group reduced their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Rothschild & Co Redburn upped their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Piper Sandler reduced their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. Finally, Truist Financial upped their price objective on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $355.19.

Amgen Price Performance

Shares of Amgen stock opened at $339.30 on Monday. The firm has a market cap of $183.11 billion, a price-to-earnings ratio of 23.61, a P/E/G ratio of 3.41 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The stock has a 50-day simple moving average of $345.10 and a 200-day simple moving average of $344.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts expect that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is currently 70.15%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is currently owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.